Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines

Bioorganic & Medicinal Chemistry Letters
2001.0

Abstract

Anilinoquinazolines currently of interest as inhibitors of tyrosine kinases have been found to be allosteric inhibitors of the enzyme fructose 1,6-bisphosphatase. These represent a new approach to inhibition of F16BPase and serve as leads for further drug design. Enzyme inhibition is achieved by binding at an unidentified allosteric site.

Knowledge Graph

Similar Paper

Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines
Bioorganic & Medicinal Chemistry Letters 2001.0
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction
Journal of Medicinal Chemistry 2020.0
Synthesis and structure–activity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles
European Journal of Medicinal Chemistry 2014.0
Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
European Journal of Medicinal Chemistry 2015.0
Novel Heteroaromatic Organofluorine Inhibitors of Fructose-1,6-bisphosphatase
Journal of Medicinal Chemistry 2009.0
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
Bioorganic & Medicinal Chemistry 2014.0
A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase
Bioorganic & Medicinal Chemistry 2009.0
Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects
European Journal of Medicinal Chemistry 2019.0
Discovery of Novel Indole Derivatives as Fructose-1,6-bisphosphatase Inhibitors and X-ray Cocrystal Structures Analysis
ACS Medicinal Chemistry Letters 2022.0
Designing inhibitors against fructose 1,6-bisphosphatase: Exploring natural products for novel inhibitor scaffolds
European Journal of Medicinal Chemistry 2010.0